Your session is about to expire
← Back to Search
Biomarker Analysis for Cervical Cancer
N/A
Waitlist Available
Led By Kathleen Schmeler
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Women with a diagnosis of high grade intraepithelial lesion (HSIL) from a routine pap test
Women with histologically confirmed cervical, vaginal or vulvar high-grade dysplasia, invasive squamous cell carcinoma, invasive adenocarcinoma, or adenocarcinoma-in-situ (AIS). All stages and grades will be eligible
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial looks at how often anal cancer occurs in patients with cervical, vaginal, or vulvar cancer. Samples from patients will be studied in the lab to learn more about the human papillomavirus.
Who is the study for?
This trial is for women diagnosed with high-grade lesions or cancer of the cervix, vagina, or vulva. Participants can have any stage of squamous cell carcinoma, adenocarcinoma, or in-situ adenocarcinoma and must consent to the study. Men and those with prior anal dysplasia/cancer or HPV-related throat cancer are excluded.Check my eligibility
What is being tested?
The study is collecting tissue samples from patients to analyze biomarkers related to human papillomavirus (HPV). It aims to understand how often anal cancer occurs in patients who have cervical, vaginal, or vulvar cancers.See study design
What are the potential side effects?
Since this trial involves biospecimen collection rather than drug testing, typical medication side effects are not expected. However, there may be minor discomforts associated with sample collection procedures.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with a high-grade lesion from a pap test.
Select...
I have a confirmed diagnosis of advanced cervical, vaginal, or vulvar cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Prevalence of invasive squamous cell carcinoma of the anus
Sensitivity and specificity of anal human papillomavirus (HPV) testing to diagnose anal dysplasia
Sensitivity and specificity of anal pap testing to diagnose anal dysplasia
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Screening (biospecimen collection)Experimental Treatment2 Interventions
Patients undergo collection of anal, cervical, vaginal, and oral samples during their scheduled pelvic exam.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 2
~1730
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,971 Previous Clinical Trials
1,786,807 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,658 Previous Clinical Trials
40,924,080 Total Patients Enrolled
Kathleen SchmelerPrincipal InvestigatorM.D. Anderson Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with a high-grade lesion from a pap test.I have a confirmed diagnosis of advanced cervical, vaginal, or vulvar cancer.I am not a male.I have had squamous cell cancer or pre-cancer in my anal area before.My throat cancer is related to HPV.
Research Study Groups:
This trial has the following groups:- Group 1: Screening (biospecimen collection)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger